Efforts to enlist the immune system to treat cancer are showing promise in a widening range of tumor types, according to early studies from three major pharmaceutical companies, supporting expectations that the strategy may have broad application against the disease..  Bristol-Myers Squibb Co., Merck & Co., Roche Holding AG and other companies are racing to bring new immunotherapy drugs to what analysts predict will be a multibillion-dollar market. So far, these drugs have shown the most promise in melanoma, a deadly skin...
  